Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Immunotherapy With Deferred Salvage Radiotherapy in Recurrent Nasopharyngeal Carcinoma
NCT07528183Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2032
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, tislelizumab, camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jul 2026; status: recruiting.
02
Drugs
toripalimabtislelizumabcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07528183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528183.